Wearing a Compression Garment for Patients With Hypermobility Type of Ehlers-Danlos Syndrome

Overview

The Ehlers-Danlos syndrome (EDS) is a rare genetic disease caused by an anomaly of the connective tissue. This syndrome has different forms. Hypermobility type is the most common. It is characterized by generalized joint hypermobility, associated with a chronic pain syndrome. Pains appear as the most frequent demonstration of this syndrome, the worst lived and the most crippling.

Faced with insufficient effect of drug treatment, other alternatives have been proposed to relieve these patients. Compression garments have been developed. They appear as medical devices targeted specifically for patients with hypermobility EDS type: in the symptomatic treatment of joint pain, in stabilizing joints by proprioceptive effect and of muscle globulization, and in the functional improvement.

The VETCOSED study is a quasi-experimental study of type "Before / After", monocentric, open. The study is realized in the Centre Médico-Chirurgical et de Réadaptation des Massues – Croix Rouge Française de Lyon, in association with the Pôle Information Médicale Evaluation Recherche des Hospices Civils de Lyon. This study concerns about 40 patients with EDS hypermobility type, which will be followed for 8 weeks: 4 weeks during which they will wear a compression custom-made garment (short-sleeved vest CICATREX SED®), and 4 weeks during which they do not carry this garment.

The main objective is to demonstrate the effectiveness of compression garments in the EDS hypermobility type, especially in terms of symptomatic improvement joint pain.

The main outcomes expected of this study are:

- an improvement of the power and the peaks of couple of muscles rotators of shoulders.

- a decrease of the pains and the defects of articular stability of the shoulder

- an improvement of the quality of life and the functional independence of these patients

Full Title of Study: “Effectiveness of Wearing a Compression Garment (SED CICATREX® Model) for Patients With Hypermobility Type of Ehlers-Danlos Syndrome”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Supportive Care
    • Masking: None (Open Label)
  • Study Primary Completion Date: January 2018

Interventions

  • Device: short-sleeved vest CICATREX SED®)
    • Each patient wears a compression custom-made garment (short-sleeved vest CICATREX SED®) according to the medical prescription during the first 4 weeks (BEFORE phase). Then each patient should not wear the compression garment for the next 4 weeks (AFTER phase).

Arms, Groups and Cohorts

  • Experimental: Patients with EDS hypermobility type
    • Patients with EDS hypermobility type wearing compression garment then compression garment removal

Clinical Trial Outcome Measures

Primary Measures

  • Power (in watts) of the external rotators of the shoulder of the dominant arm measured by concentric isokinetic evaluation at a constant angular velocity of 180 °/s
    • Time Frame: 2 months follow-up
    • The evaluations will be conducted 3 times: at the inclusion (D0) at the end of the BEFORE phase (4 weeks with the compression garment: D0 + 28) at the end of the AFTER phase (4 weeks without the compression garment: D0 + 56) For each measurement, evaluations will be made with then without the compression garment.

Secondary Measures

  • Level of pain expressed in the shoulders of patients
    • Time Frame: D0,D28,D56
    • Evaluation of the level of pain each month by the physician investigator on Visual Analogue Scale : at the inclusion (D0) at the end of the BEFORE phase (4 weeks with the compression garment: D0 + 28) at the end of the AFTER phase (4 weeks without the compression garment: D0 + 56)
  • Score of quality of life measured by the medical outcomes study Short-Form General Health Survey (SF-36 scale)
    • Time Frame: D0,D28,D56
    • The score of quality of life is measured by self-administered questionnaire (SF-36 scale) at each follow-up visit: at the inclusion (D0) at the end of the BEFORE phase (4 weeks with the compression garment: D0 + 28) at the end of the AFTER phase (4 weeks without the compression garment: D0 + 56)
  • Score of satisfaction measured by the Quebec User Evaluation of Satisfaction with assistive Technology (QUEST)
    • Time Frame: D0,D28,D56
    • The score of satisfaction is measured by self-administered questionnaire (QUEST) at each follow-up visit: at the inclusion (D0) at the end of the BEFORE phase (4 weeks with the compression garment: D0 + 28) at the end of the AFTER phase (4 weeks without the compression garment: D0 + 56)
  • Functional independence score measured by Health Assessment Questionnaire (HAQ)
    • Time Frame: D0,D28,D56
    • The score of functional independence is measured by self-administered questionnaire (HAQ) at each follow-up visit: at the inclusion (D0) at the end of the BEFORE phase (4 weeks with the compression garment: D0 + 28) at the end of the AFTER phase (4 weeks without the compression garment: D0 + 56)

Participating in This Clinical Trial

Inclusion Criteria

  • Ehlers-Danlos syndrome hypermobility type confirmed the diagnosis of a geneticist
  • with an instability of one or both shoulders, painful or considered invalidating by the patient (recurrent dislocation or subluxation : at least once / month or at least 12 times / year)
  • having a joint hypermobility syndrome (abnormal mobility and in a non-physiological axis), with a Beighton score of greater than or equal to 5 of 9
  • age greater than or equal to 18 years
  • size greater than or equal to 1 m 40
  • sufficient understanding of the French language in order to respond to self-report questionnaires

Exclusion Criteria

  • hyperalgic episode in progress
  • unstable cardiac disease
  • previous history of shoulder surgery
  • severe skin lesions,
  • pregnancy in progress

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Hospices Civils de Lyon
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Emmanuelle CHALEAT-VALAYER, Dr, Principal Investigator, Centre Médico-Chirurgical de Réadaptation des Massues
  • Overall Contact(s)
    • Emmanuelle CHALEAT-VALAYER, Dr, 472.38.46.28, chaleat-valayer.e@cmcr-massues.com

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.